First-in-human phase I study of PD-1/CTLA-4 bispecific volrustomig in 86 patients with advanced cancer: common treatment-related adverse events were pruritus (30.2%) and hypothyroidism (26.7%); 33.7% discontinued, one died; 19.8% had objective responses.
RCTn = 86
Tran et al. Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody